Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery
(1) Objective: Bacterial resistance to conventional antibiotic therapy is an increasingly significant worldwide challenge to human health. The objective is to evaluate whether bacteriophage therapy could complement or be a viable alternative to conventional antibiotic therapy in critical cases of ba...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/9/5/232 |
| _version_ | 1797568726761996288 |
|---|---|
| author | Evgenii Rubalskii Stefan Ruemke Christina Salmoukas Erin C. Boyle Gregor Warnecke Igor Tudorache Malakh Shrestha Jan D. Schmitto Andreas Martens Sebastian V. Rojas Stefan Ziesing Svetlana Bochkareva Christian Kuehn Axel Haverich |
| author_facet | Evgenii Rubalskii Stefan Ruemke Christina Salmoukas Erin C. Boyle Gregor Warnecke Igor Tudorache Malakh Shrestha Jan D. Schmitto Andreas Martens Sebastian V. Rojas Stefan Ziesing Svetlana Bochkareva Christian Kuehn Axel Haverich |
| author_sort | Evgenii Rubalskii |
| collection | DOAJ |
| description | (1) Objective: Bacterial resistance to conventional antibiotic therapy is an increasingly significant worldwide challenge to human health. The objective is to evaluate whether bacteriophage therapy could complement or be a viable alternative to conventional antibiotic therapy in critical cases of bacterial infection related to cardiothoracic surgery. (2) Methods: Since September 2015, eight patients with multi-drug resistant or especially recalcitrant <i>Staphylococcus aureus</i>, <i>Enterococcus faecium</i>, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, and <i>Escherichia coli</i> infections were treated with bacteriophage preparations as a therapy of last resort according to Article 37 of the Declaration of Helsinki. Patients had infections associated with immunosuppression after organ transplantation or had infections of vascular grafts, implanted medical devices, and surgical wounds. Individualized phage preparations were administered locally, orally, or via inhalation for different durations depending on the case. All patients remained on conventional antibiotics during bacteriophage treatment. (3) Results: Patients ranged in age from 13 to 66 years old (average 48.5 ± 16.7) with seven males and one female. Eradication of target bacteria was reached in seven of eight patients. No severe adverse side effects were observed. (4) Conclusions: Phage therapy can effectively treat bacterial infections related to cardiothoracic surgery when conventional antibiotic therapy fails. |
| first_indexed | 2024-03-10T20:01:02Z |
| format | Article |
| id | doaj.art-1b724a31b35c4e4b9fa066d49b106e26 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T20:01:02Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-1b724a31b35c4e4b9fa066d49b106e262023-11-19T23:31:24ZengMDPI AGAntibiotics2079-63822020-05-019523210.3390/antibiotics9050232Bacteriophage Therapy for Critical Infections Related to Cardiothoracic SurgeryEvgenii Rubalskii0Stefan Ruemke1Christina Salmoukas2Erin C. Boyle3Gregor Warnecke4Igor Tudorache5Malakh Shrestha6Jan D. Schmitto7Andreas Martens8Sebastian V. Rojas9Stefan Ziesing10Svetlana Bochkareva11Christian Kuehn12Axel Haverich13Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, 30625 Hannover, GermanyG.N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Moscow 125212, RussiaDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, GermanyDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany(1) Objective: Bacterial resistance to conventional antibiotic therapy is an increasingly significant worldwide challenge to human health. The objective is to evaluate whether bacteriophage therapy could complement or be a viable alternative to conventional antibiotic therapy in critical cases of bacterial infection related to cardiothoracic surgery. (2) Methods: Since September 2015, eight patients with multi-drug resistant or especially recalcitrant <i>Staphylococcus aureus</i>, <i>Enterococcus faecium</i>, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, and <i>Escherichia coli</i> infections were treated with bacteriophage preparations as a therapy of last resort according to Article 37 of the Declaration of Helsinki. Patients had infections associated with immunosuppression after organ transplantation or had infections of vascular grafts, implanted medical devices, and surgical wounds. Individualized phage preparations were administered locally, orally, or via inhalation for different durations depending on the case. All patients remained on conventional antibiotics during bacteriophage treatment. (3) Results: Patients ranged in age from 13 to 66 years old (average 48.5 ± 16.7) with seven males and one female. Eradication of target bacteria was reached in seven of eight patients. No severe adverse side effects were observed. (4) Conclusions: Phage therapy can effectively treat bacterial infections related to cardiothoracic surgery when conventional antibiotic therapy fails.https://www.mdpi.com/2079-6382/9/5/232phage therapybacterial infectioncardiothoracic surgeryimplant-associated infectiontransplant-associated infectionsurgical site infection |
| spellingShingle | Evgenii Rubalskii Stefan Ruemke Christina Salmoukas Erin C. Boyle Gregor Warnecke Igor Tudorache Malakh Shrestha Jan D. Schmitto Andreas Martens Sebastian V. Rojas Stefan Ziesing Svetlana Bochkareva Christian Kuehn Axel Haverich Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery Antibiotics phage therapy bacterial infection cardiothoracic surgery implant-associated infection transplant-associated infection surgical site infection |
| title | Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery |
| title_full | Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery |
| title_fullStr | Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery |
| title_full_unstemmed | Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery |
| title_short | Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery |
| title_sort | bacteriophage therapy for critical infections related to cardiothoracic surgery |
| topic | phage therapy bacterial infection cardiothoracic surgery implant-associated infection transplant-associated infection surgical site infection |
| url | https://www.mdpi.com/2079-6382/9/5/232 |
| work_keys_str_mv | AT evgeniirubalskii bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT stefanruemke bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT christinasalmoukas bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT erincboyle bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT gregorwarnecke bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT igortudorache bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT malakhshrestha bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT jandschmitto bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT andreasmartens bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT sebastianvrojas bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT stefanziesing bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT svetlanabochkareva bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT christiankuehn bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery AT axelhaverich bacteriophagetherapyforcriticalinfectionsrelatedtocardiothoracicsurgery |